Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Friday, November 1st, Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88.

Nurix Therapeutics Trading Up 1.8 %

Shares of NASDAQ:NRIX traded up $0.36 during mid-day trading on Thursday, hitting $20.01. 695,140 shares of the company traded hands, compared to its average volume of 662,076. The stock has a market cap of $1.42 billion, a P/E ratio of -6.88 and a beta of 2.14. The stock has a 50-day moving average price of $20.14 and a two-hundred day moving average price of $22.40. Nurix Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Analysts Set New Price Targets

NRIX has been the subject of several research analyst reports. Stephens reissued an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Stifel Nicolaus lifted their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. BTIG Research began coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. Amalgamated Bank lifted its holdings in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares during the last quarter. Quarry LP raised its stake in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. International Assets Investment Management LLC grew its position in Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after buying an additional 4,119 shares during the period. Finally, Quest Partners LLC increased its holdings in Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after buying an additional 1,312 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.